At the news
? BULLISHIMPACT 7/10 PRESS-RELEASE filed Apr 8, 2026 at 16:30 ET
MacroGenics announced that the FDA has lifted the partial clinical hold on its Phase 2 LINNET study of lorigerlimab for gynecologic cancers, allowing resumption of new patient enrollment under a revised protocol. The company remains on track to provide a mid-2026 clinical update.
- FDA lifted the partial clinical hold on the Phase 2 LINNET study of lorigerlimab.
- Enrollment of new patients will resume with additional risk-mitigation measures for hematologic and cardiac toxicities.
- Study evaluates lorigerlimab in platinum-resistant ovarian cancer and clear cell gynecologic cancer with an ORR primary endpoint.
- 41 patients have already been dosed in the LINNET study; over 300 patients dosed across all lorigerlimab trials to date.
Before · The news · First close · A day later · A week later
Replay the market's reaction
Step through every 5 minutes around the news, then see how it compares with similar events.
Subscribe for Full Access